Early biomarker changes in frontotemporal dementia

FTD-RisC
Early biomarker changes in frontotemporal dementia

www.alzheimercentrumzwn.nl
[email protected]
Memorabel
Memorabel

Only through study

Netherlands

Yes
Apply to PI or co-ordinator at resource| Access through collaboration with PI only| Local/ regional access| National access| International access| Access for pilot studies permitted| Resource has own ethics approval so usually no need for separate external ethics approval
No policy exists
Yes
Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Living donors: cerebro-spinal fluid| Living donors: other (Skin biopsy)
Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples:(derivatives of primary samples)| Secondary samples: plasma| Secondary samples: DNA| Secondary samples: RNA
Yes
Yes, for all the cohort
Aim to find early disease-related differences and biomarkers in MRI, blood, cerebrospinal fluid and neuropsychological assessment in presymptomatic familial frontotemporal dementia

6

Dopper et al., 2014 – Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia – Neurology
Rohrer et al., 2015 – Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis – Lancet Neurology
Dopper et al., 2016 – Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study – NeuroImage Clinical
Jiskoot et al., 2016 – Presymptomatic cognitive decline in familial frontotemporal dementia: A longitudinal study – Neurology
Meeter et al., 2016 – Neurofilament light chain: a biomarker for genetic frontotemporal dementia – Annals of Clinical and Translational Neurology
Meeter et al., 2016 – Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers – Dementia and Geriatric Cognitive disorders Extra

1-1,000
200-500
MRI, DNA, RNA, plasma, serum, CSF, NPA, skin biopsy
No
No

Prospective cohort
Age| Sex
Yes
Control participants are 50% at-risk subjects, without carrying the gene mutation
Data collection ongoing| Data analysis ongoing
Yes – intend to apply for funding

Data summarised in database

Database is web-based

Database on spreadsheet (e.g. excel)

Database on paper

No

Data is web-based

Early biomarker changes in frontotemporal dementia
Motor neurone diseases| Alzheimer’s disease and other dementias

Case Control Studies
Netherlands
Alzheimer’s disease & other dementias|Motor neurone diseases
2016